Multicenter retrospective observational study of conservative management for acute type A intramural hematoma
The Journal of Thoracic and Cardiovascular Surgery · 2025
DOI: 10.1016/j.jtcvs.2025.03.013 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Thoracic and Cardiovascular Surgery, 2025. Verfasst von Noritsugu Naito und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery, Shizuoka Medical Center, Shizuoka, Japan. Electronic address: nori.naito@gmail.com. Hauptthemen laut MEDLINE: Hematoma, Conservative Treatment, Aortic Diseases. Die Arbeit nennt 24 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES: To investigate the outcomes of patients treated conservatively for type A intramural hematoma (TAIMH). METHODS: A multicenter retrospective analysis was conducted on patients with TAIMH between April 2011 and June 2023. Of 166 patients who underwent initial medical treatment, 122 were treated without surgery during the index admission (MT group), the primary focus of this study. For comparison, 44 patients who crossed over to surgery (CO group) and 91 patients who underwent immediate surgery (EM group) were analyzed as well. RESULTS: The mean maximum ascending aortic diameter (AOD) and hematoma thickness were 44.4 ± 5.5 mm and 7.9 ± 3.3 mm in the MT group, 47.2 ± 5.2 mm and 8.9 ± 3.4 mm in the CO group, and 49.2 ± 5.5 mm and 12.7 ± 5.5 mm in the EM group. The in-hospital mortality rate was 9.8% in the MT group, 9.1% in the CO group and 8.8% in the EM group. the In MT group, multivariable logistic regression identified maximum AOD as a predictor of in-hospital death (P < .05), aortic death (P < .05), and the composite outcome of in-hospital death and disease progression (P = .02). The 5-year survival rate was 85.5% in the MT group, 89.1% in the CO group, and 88.3% in the EM group. In the MT group, multivariable Cox regression analysis identified maximum AOD as a predictor of overall survival (hazard ratio, 1.10; 95% confidence interval, 1.00-1.21; P = .05). CONCLUSIONS: Conservative management of patients with TAIMH offers favorable outcomes; however, a larger maximum AOD was associated with worse short-term and mid-term outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Surgery, Shizuoka Medical Center, Shizuoka, Japan. Electronic address: nori.naito@gmail.com.
- Department of Cardiovascular Surgery, Kitasato University School of Medicine, Kanagawa, Japan.
- Department of Cardiovascular Surgery, National Center for Global Health and Medicine, Tokyo, Japan.
- Department of Cardiovascular Surgery, Yokohama Rosai Hospital, Kanagawa, Japan.
- Division of Cardiovascular Surgery, Department of Surgery, Kochi Medical School, Kochi, Japan.
- Department of Cardiovascular Surgery, NTT Medical Center Tokyo, Tokyo, Japan.
Zitieren
APA
Naito, N., Motoji, Y., Tamura, T., Okada, H., Miura, Y., Matsushita, H., Kitamura, T., & Society for Promotion and Enhancement of Cardiovascular Surgery Group (2025). Multicenter retrospective observational study of conservative management for acute type A intramural hematoma. The Journal of Thoracic and Cardiovascular Surgery. https://doi.org/10.1016/j.jtcvs.2025.03.013
Vancouver
Naito N, Motoji Y, Tamura T, Okada H, Miura Y, Matsushita H, et al. Multicenter retrospective observational study of conservative management for acute type A intramural hematoma. The Journal of Thoracic and Cardiovascular Surgery. 2025. doi:10.1016/j.jtcvs.2025.03.013
BibTeX
@article{Naito2025,
author = {Naito, Noritsugu and Motoji, Yusuke and Tamura, Tomoki and Okada, Hiroshi and Miura, Yujiro and Matsushita, Hiroshi and Kitamura, Tadashi and Society for Promotion and Enhancement of Cardiovascular Surgery Group, Society for Promotion and Enhancement of Cardiovascular Surgery Group},
title = {Multicenter retrospective observational study of conservative management for acute type A intramural hematoma},
journal = {The Journal of Thoracic and Cardiovascular Surgery},
year = {2025},
doi = {10.1016/j.jtcvs.2025.03.013}
}
EUVIMED